Actively Recruiting
LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)
Led by University of Illinois at Chicago · Updated on 2026-04-13
2500
Participants Needed
2
Research Sites
620 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.
CONDITIONS
Official Title
LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 50 and 80 years at the time of consent
- Meets at least one lung cancer screening eligibility: USPSTF criteria of 20 or more pack-years and currently smoking or quit within 15 years; Potter criteria of 20 years smoking regardless of intensity; or ACS criteria of 20 or more pack-years with no quit time restriction
- Receiving or scheduled for low-dose CT scan through the UI Health Lung Screening Program
- Willing to watch an educational video about Sybil AI scoring and lung cancer screening, complete surveys if chosen, and provide blood samples optionally
- Able to provide written informed consent and HIPAA authorization
- Women of childbearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test
- Able to understand and follow study procedures for the entire study length as judged by study staff
You will not qualify if you...
- Unable to undergo low-dose CT scan
- Current diagnosis or history of lung cancer within 5 years prior to enrollment
- Life expectancy less than 1 year
- Active lung infection requiring systemic therapy
- Vulnerable populations such as prisoners and pregnant or nursing women due to radiation exposure risks
- Major comorbid conditions as determined by the study principal investigator
- Any mental or medical condition preventing informed consent or study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of Illinois Cancer Center
Chicago, Illinois, United States, 60612
Actively Recruiting
2
UI Health 55th and Pulaski Health Collaborative
Chicago, Illinois, United States, 60629
Actively Recruiting
Research Team
M
Mary Pasquinelli, DNP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here